This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction/Beyond SSRIs

A. John Rush, M.D.

Published: January 1, 1998

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

This supplement (1) reviews new developments in our understanding of the mechanisms of action, therapeutic efficacy, and satety of antidepressants (especially bupropion), (2) provides an update on antidepressant interactions, (3) presentsnew data on bupropion for smoking cessation and attention-deficit/hyperactivity disorder(ADHD), and (4) evaluates proposed medication management plans (e.g., algorithms)for the treatment of depressed phase bipolar disorder.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...